University of California, San Francisco

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).

1,713 total trials 272 currently recruiting 1130 completed early-phase tilt top decile by trial count

University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.

University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.

Top-decile sponsor footprint

University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,713 total, page 17 of 35

COMPLETED NA

Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men

NCT03143205

TERMINATED

The Relation of GnRH Treatment to QTc Interval in Transgender Females

NCT03078829

COMPLETED NA

Women's Lifestyle Balance Study

NCT03184337

COMPLETED NA

Comparison of 3 Modes of Genetic Counseling in High-Risk Public Hospital Patients

NCT03006913

COMPLETED NA

Survivor Choices for Eating and Drinking - Colorectal Cancer

NCT02965521

COMPLETED NA

Cardiac Recovery Through Dietary Support

NCT03759925

COMPLETED NA

Improving Preterm Infant Outcomes With Family Integrated Care and Mobile Technology

NCT03418870

COMPLETED NA

Preoperative Guided Imagery in Patients Undergoing Urologic Surgery

NCT05072639

TERMINATED Phase 2

Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial

NCT02950480

COMPLETED NA

Thalamic Deep Brain Stimulation for Secondary Dystonia in Children and Young Adults

NCT03078816

COMPLETED NA

Health Coaching for Positive Airway Pressure Adherence

NCT04067128

COMPLETED Phase 4

Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation

NCT03136068

COMPLETED NA

Delish Study: Diabetes Education to Lower Insulin, Sugars, and Hunger

NCT03207711

TERMINATED NA

Pilot to Examine Risk and Feasibility of Remote Management of BP From CKD Through ESRD

NCT02975505

COMPLETED NA

Mobile-based Peer Mentoring for Smoking Cessation

NCT03048786

COMPLETED NA

I-scan for Adenoma Detection

NCT02811419

COMPLETED NA

Learning From Online Video Education for Controlled Ovarian Stimulation

NCT02979990

TERMINATED NA

Effectiveness of an EHR Interface to Reduce Dosage of Hydroxychloroquine

NCT04310462

COMPLETED Phase 1

Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors

NCT02947373

COMPLETED NA

Regional Anesthesia (Supra-Orbital and Infra-Orbital Nerve Block) (SION) for Pain Management in Trans-sphenoidal Hypophysectomy

NCT04670614

COMPLETED

Predictors of Outcomes in MBSR Participants From Teacher Factors

NCT03384771

COMPLETED Phase 1

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

NCT02602327

COMPLETED

Progression and Etiology of Cortical Porosity in Diabetic Bone Disease

NCT04208230

COMPLETED Phase 1

Oxytocin HIV Meth Study

NCT02881177

COMPLETED

Sorting and Expression Profiling of Airway Cells From Humans (The SEARCH Study)

NCT02791542

COMPLETED

Analysis of Inflammation and Microbiome in Patients With Sinusitis and Asthma

NCT02548598

COMPLETED NA

Characterizing the Synergistic Effects of Physical and Cognitive Training on Attention and Working Memory

NCT03032796

COMPLETED Phase 3

High-dose Erythropoietin for Asphyxia and Encephalopathy

NCT02811263

COMPLETED NA

Interventions To Help Asthma Clinical Adherence

NCT02999789

COMPLETED NA

Improving Mental Health and Well-Being Via Awe Walks

NCT03550144

COMPLETED NA

Use of Fish Oil to Reduce Inflammation During Endovascular Abdominal Aortic Repair

NCT03208920

TERMINATED NA

Validation of Combined PET-MR Quantitative Parameters for Cardiac Applications

NCT02062008

COMPLETED NA

The Share Health Study: Teen Social Connections and Health

NCT02791971

COMPLETED NA

Improving Engagement in HIV Care for High-risk Women

NCT03081559

COMPLETED Phase 4

The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics

NCT02956278

COMPLETED Phase 4

Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study

NCT02806024

COMPLETED NA

Interactive Mobile Doctor (iMD) for Asian Smokers

NCT02966132

COMPLETED NA

Health Outcomes Patient Education

NCT02976220

TERMINATED Phase 2

Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair

NCT02825849

TERMINATED Early Phase 1

MRI With C13 Pilot Study Prostate Cancer

NCT02450201

COMPLETED Phase 4

Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients

NCT02866695

COMPLETED Phase 2

A Study of Oxidative Pathways in MS Fatigue

NCT02804594

COMPLETED NA

Enhancing Self-Management Support in Diabetes Through Patient Engagement

NCT02834923

COMPLETED NA

Research on Expecting Moms and Sleep Therapy

NCT02805998

COMPLETED Phase 4

Immunologic Response to Secukinumab in Plaque Psoriasis

NCT02592018

COMPLETED NA

Emotion Tracking Study for Residents

NCT02947477

TERMINATED NA

Comparing Intra-vaginal Culture of Embryos to In-vitro Culture of Embryos With Minimal Stimulation

NCT02802176

COMPLETED Phase 2

Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients

NCT02919111

COMPLETED Phase 2

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

NCT02918357

COMPLETED NA

Integrative Approaches For Cancer Survivorship 2: Project 1

NCT02897635

← Previous Page 17 of 35 Next →

Phase Distribution

PhaseTrial count
Phase 1 193
Phase 2 166
Phase 3 44
Phase 4 152

What is open in the University of California, San Francisco pipeline

272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).

Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (18 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, San Francisco: open-pipeline peers nationwide

Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share University of California, San FranciscoDuke UniversityStanford UniversityVA Office of Research and DevelopmentPfizerUniversity of OregonFox Chase Cancer CenterYoungstown State UniversityECOG-ACRIN Cancer Research Group
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,713 trials (± recruiting share)

Sponsors near 16% open enrollment (± trial volume)

What to do with this University of California, San Francisco page

1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.

  • 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.